Insite Vision (INSV) Inactive

We are an ophthalmic product development company advancing ophthalmic pharmaceutical products to address unmet eye care needs. Our current portfolio of products is based on our proprietary DuraSite® sustained drug delivery technology. Our near term strategy is to primarily focus on filing New Drug Applications (NDAs) for BromSite and DexaSite with the United States Food and Drug Administration (FDA). We face significant challenges related to our lack of financial resources. We expect that our cash on hand, anticipated cash flow from operations and the net proceeds from our existing debt financing arrangements (for further discussion, see Note 1 and 8 to the consolidated financial statements included in this annual report) will only enable us to continue our operations as currently planned until approximately May 2015. Our independent auditors included an explanatory paragraph in their audit report related to our consolidated financial statements for the year ended December 31, 2014, referring to our recurring losses from operations, available cash balance and accumulated deficit and a substantial doubt about our ability to continue as a going concern.